Pancreatic Cancer Research

ResearcherLinköping UniversityActive in the last 2 years

Nils O. Elander

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9345-0278; OpenAlex author ID A5140647705. Sources: OpenAlex.

Their work

Papers
17 (first author 3, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
47
Papers, trials and grants by year

2018: 2 papers · 2019: 1 paper · 2020: 3 papers · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers · 2026: 4 papers

Papers 17

  1. Mistletoe extract in patients with advanced pancreatic cancer: Health-related quality of life in a double-blind, randomized, placebo-controlled trial (MISTRAL). Co-author DOI 10.1177/02692163261437609↗
  2. Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-20191-5↗
  3. ASO Visual Abstract: Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-20304-0↗
  4. ASO Author Reflections: Understanding the Prognostic Role of Claudin 18.2 in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-20312-0↗
  5. Prospective evaluation of surgical treatment of liver metastasizing pancreatic cancer - ScanPan study protocol. Co-author DOI 10.1186/s12893-025-02983-w↗
  6. PCD-CT Versus EID-CT in Imaging of Pancreatic Ductal Adenocarcinoma: A Prospective Comparative Pilot Study. Co-author DOI 10.21873/anticanres.17536↗
  7. Intratumoural expression of dihydropyrimidine dehydrogenase is an independent prognostic factor in resected pancreatic ductal adenocarcinoma treated with adjuv… Last author DOI 10.3892/ol.2024.14845↗
  8. Mistletoe Extract in Patients With Advanced Pancreatic Cancer: a Double-Blind, Randomized, Placebo-Controlled Tial (MISTRAL) Co-author DOI 10.3238/arztebl.m2024.0080↗
  9. Impact of resection margins and para-aortic lymph node metastases on recurrence patterns and prognosis in resectable pancreatic cancer - a long-term population… Last author DOI 10.1016/j.hpb.2023.08.006↗
  10. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. First author DOI 10.3390/cancers13225758↗
  11. Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer. Last author DOI 10.5306/wjco.v12.i9.787↗
  12. Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel. Last author DOI 10.1186/s12885-020-07426-8↗
  13. Efficacy of mistletoe extract as a complement to standard treatment in advanced pancreatic cancer: study protocol for a multicentre, parallel group, double-bli… Co-author DOI 10.1186/s13063-020-04581-y↗
  14. Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer. Last author DOI 10.3389/fonc.2020.01176↗
  15. Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. Last author DOI 10.1186/s12885-018-5244-2↗
  16. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. First author DOI 10.1038/s41416-018-0004-2↗
  17. Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pa… First author DOI 10.1038/s41416-018-0005-1↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hakon Blomstrand · 10 shared papers, 2019–2026 · strength 2.09
  2. Daniel Öhlund · 5 shared papers, 2025–2026 · strength 1.20
  3. Bergþór Björnsson · 5 shared papers, 2020–2025 · strength 1.07
  4. Oskar Franklin · 4 shared papers, 2025–2026 · strength 1.00
  5. Malin Sund · 4 shared papers, 2025–2026 · strength 1.00
  6. Asif Halimi · 4 shared papers, 2025–2026 · strength 0.97
  7. Jun Yoshino · 3 shared papers, 2026 · strength 0.77
  8. Hanna E. Seppänen · 3 shared papers, 2026 · strength 0.77
  9. Caj H. Haglund · 3 shared papers, 2026 · strength 0.77
  10. Ella Kesti · 3 shared papers, 2026 · strength 0.77
  11. Kathrin Wode · 3 shared papers, 2020–2026 · strength 0.59
  12. Gunver Sophia Kienle · 3 shared papers, 2020–2026 · strength 0.59
  13. Lena Sharp · 3 shared papers, 2020–2026 · strength 0.59
  14. Per Fransson · 3 shared papers, 2020–2026 · strength 0.59
  15. Roger Henriksson · 3 shared papers, 2020–2026 · strength 0.59
  16. Britt‐Marie Bernhardson · 2 shared papers, 2020–2024 · strength 0.31
  17. Emma Gränsmark · 2 shared papers, 2020 · strength 0.27
  18. Mischa Woisetschläger · 1 shared paper, 2025 · strength 0.27
  19. Alan Anthoney · 3 shared papers, 2018–2021 · strength 0.21
  20. David Goldstein · 3 shared papers, 2018–2021 · strength 0.21
  21. Paula Ghaneh · 3 shared papers, 2018–2021 · strength 0.21
  22. Karen Aughton · 3 shared papers, 2018–2021 · strength 0.21
  23. Bengt L. G. Glimelius · 3 shared papers, 2018–2021 · strength 0.21
  24. Daniel H. Palmer · 3 shared papers, 2018–2021 · strength 0.21
  25. Niall Christopher Tebbutt · 3 shared papers, 2018–2021 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.